3 New Strong Buy Ratings from Top-Rated Analysts: 09/25/2026

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Warrior Met Coal (HCC) — Premium coal miner with 39% upside target
• QuinStreet (QNST) — Fresh Strong Buy upgrade on 40% ROE
• Bristol-Myers Squibb (BMY) — Our latest Trade of the Week has legs

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

The ONLY AI opportunity you should be looking at

This is the ONLY AI wealth-building opportunity you should be watching right now.

No. It's not about Nvidia, Tesla, or Meta...

It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.

This new opportunity will change the market and make investors a lot of money.

That's why it has received a $500 billion commitment from President Trump himself...

Learn more about this little-known company here >>>

1. Warrior Met Coal (NYSE: HCC)

Warrior Met Coal produces premium metallurgical coal for the global steel industry. With a 17.2% profit margin and strengthening coal fundamentals, the company is well-positioned to capitalize on sustained demand from international steelmakers.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $88.47 — get current quote

Max 1-year forecast: $123.00

Why we're watching:

• HCC has limited, but overall bullish, coverage among the analysts we track, with 2 Strong Buy and 1 Hold recommendations. See all recommendations here
• For example, B. Riley Securities researcher Nick Giles (a top 14% rated analyst) maintained his Strong Buy recommendation with a price target suggesting the stock has roughly 40% upside potential from current levels. Giles cited "modestly higher" Blue Creek output assumptions for the price target hike.
• Industry ranking context: HCC is currently the #1 highest-rated stock in the Coking Coal industry, which has an Industry Rating of C.
• Zen Ratings highlights: HCC earns an overall A rating, equal to a Strong Buy recommendation. This tier represents stocks that have historically delivered nearly 30% annual returns, soundly beating the S&P.
• Component Grades: HCC maintains solid Bs for Financials, Growth, and Value, reflecting the company's disciplined capital allocation and stable cash generation. See all 7 Component Grades here

2. QuinStreet (NASDAQ: QNST)

QuinStreet is a global digital performance marketing enterprise specializing in client acquisition solutions and measurable online marketing results. With 40.73% return on equity and 12.2% revenue growth, the company is capturing share in the evolving digital advertising landscape.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $17.26 — get current quote

Max 1-year forecast: $21.00

Why we're watching:

• QNST has limited, but strongly bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
• For example, Lake Street researcher Eric Martinuzzi (a top 25% rated analyst) recently upgraded QNST to Strong Buy with a price target suggesting the stock could see over 20% additional upside in the coming year. 
• Industry ranking context: QNST is currently the #2 highest-rated stock in the Advertising Agency industry, which has an Industry Rating of D.
• Zen Ratings highlights: QNST receives an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
• Component Grades: QNST excels for Growth with an A grade, reflecting impressive earnings expansion of 17.17%, while maintaining a strong B for Financials driven by exceptional return on equity. See all 7 Component Grades here

3. Bristol Myers Squibb (NYSE: BMY) 

One of the world’s largest pharma companies just earned our Editor-in-Chief’s Trade of the Week designation. With an 18.9% profit margin, a 45.1% return on equity, and fresh late-stage pipeline wins, the company is executing a portfolio renewal that analysts are increasingly willing to underwrite.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $62.25 — get current quote

Max 1-year forecast: $82.00

Why we're watching:

• BMY has broad, bullish coverage among the analysts we track, with 7 Strong Buy and 5 Hold recommendations. See all recommendations here
• For example, Piper Sandler researcher David Amsellem (a top 4% rated analyst) recently reiterated his Strong Buy recommendation with a price target suggesting the stock could see greater than 30% upside in the coming year. 
• Our own Editor-in-Chief, Steve Reitmeister, is even more bullish on the stock. He named it as his Trade of the Week in our most recent WallStreetZen Live webinar … If you want to get our next pick before the crowd, join our next no-paywall event this coming Monday. Sign up here.
• Pipeline catalyst: BMY announced positive topline results from a Phase 2 trial, with the program meeting its main goal in mid-stage testing.
• Industry ranking context: BMY is currently the #1 highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
• Zen Ratings highlights: BMY earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
• Component Grades: BMY excels for Value and Sentiment with A grades, reflecting a P/E of under 14 against an industry average near 40 alongside strengthening analyst conviction, while maintaining solid Bs for Momentum, Safety, Financials, and Artificial Intelligence — a six-grade strength profile that positions it as one of the better-rounded large-cap pharma setups available. See all 7 Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.